Daiichi initiates pivotal trials for cancer drug nimotuzumab

04/26/2013 | Pharmaceutical Business Review Online

Daiichi Sankyo has started patient enrollment for two late-stage trials of nimotuzumab, its experimental drug for lung and gastric cancer. Nimotuzumab is a recombinant humanized monoclonal antibody that targets the epidermal growth factor receptor. The lung cancer trial will be carried out in Japan while the gastric cancer study will be conducted in Japan and South Korea.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr Statistician I (US/TB/00/0028/SL)
Abbott
Santa Clara, CA
Food & Drug Associate
Confidential
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA